Fludarabine + Cyclophosphamide + Tocilizumab
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory Autoimmune Diseases
Conditions
Refractory Autoimmune Diseases
Trial Timeline
Sep 4, 2025 → Aug 16, 2030
NCT ID
NCT07115745About Fludarabine + Cyclophosphamide + Tocilizumab
Fludarabine + Cyclophosphamide + Tocilizumab is a phase 1 stage product being developed by Bristol Myers Squibb for Refractory Autoimmune Diseases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07115745. Target conditions include Refractory Autoimmune Diseases.
What happened to similar drugs?
3 of 20 similar drugs in Refractory Autoimmune Diseases were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07115745 | Phase 1 | Recruiting |
Competing Products
20 competing products in Refractory Autoimmune Diseases